GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Interest Expense

ME Therapeutics Holding (XCNQ:METX) Interest Expense : C$-0.01 Mil (TTM As of Feb. 2025)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ME Therapeutics Holding's interest expense for the three months ended in Feb. 2025 was C$ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2025 was C$-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ME Therapeutics Holding's Operating Income for the three months ended in Feb. 2025 was C$ -0.21 Mil. ME Therapeutics Holding's Interest Expense for the three months ended in Feb. 2025 was C$ -0.00 Mil. ME Therapeutics Holding did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


ME Therapeutics Holding Interest Expense Historical Data

The historical data trend for ME Therapeutics Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Interest Expense Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24
Interest Expense
-0.01 -0.01 -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ME Therapeutics Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ME Therapeutics Holding  (XCNQ:METX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ME Therapeutics Holding's Interest Expense for the three months ended in Feb. 2025 was C$-0.00 Mil. Its Operating Income for the three months ended in Feb. 2025 was C$-0.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2025 was C$0.04 Mil.

ME Therapeutics Holding's Interest Coverage for the quarter that ended in Feb. 2025 is calculated as

ME Therapeutics Holding did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


ME Therapeutics Holding Business Description

Traded in Other Exchanges
Address
177 Robson St., Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding Headlines

No Headlines